Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $17.75

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.75.

Several equities analysts have recently commented on ATRA shares. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Canaccord Genuity Group reduced their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, January 17th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 target price for the company. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATRA. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics during the second quarter worth about $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at $53,000. FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the period. Vestal Point Capital LP boosted its position in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares during the period. Finally, State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Stock Up 0.4 %

NASDAQ ATRA opened at $9.34 on Friday. The stock has a market cap of $53.80 million, a PE ratio of -0.36 and a beta of 0.46. Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $28.75. The business has a 50 day moving average price of $11.50 and a two-hundred day moving average price of $9.84.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the prior year, the company earned ($16.50) EPS. Sell-side analysts anticipate that Atara Biotherapeutics will post -10.39 EPS for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.